SCHEMBL7206530

SCHEMBL7206530

COc1ccccc1Oc1ccc(S(=O)(=O)C2CCN(C(N)=O)CC2(O)C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.45
HTT P42858 3/20 0.45
MMP1 P03956 5/20 0.44
MMP13 P45452 5/20 0.44
ALDH1A1 P00352 4/20 0.43
LMNA P02545 2/20 0.41
MMP3 P08254 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 1/20 0.39
MMP10 P09238 1/20 0.39
MAPT P10636 1/20 0.39
MMP2 P08253 4/20 0.39
MMP9 P14780 4/20 0.39
MMP14 P50281 2/20 0.39
MMP12 P39900 1/20 0.39
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7202596 0.91 MMP1 (0.54) TSHRHTTMMP1MMP13ALDH1A1
SCHEMBL7203058 0.90 MMP9 (0.47) TSHRMMP1MMP13ALDH1A1MMP3
SCHEMBL7207163 0.90 MMP1 (0.45) TSHRHTTMMP1MMP13ALDH1A1
SCHEMBL7199700 0.90 MMP1 (0.42) MMP1MMP13ALDH1A1LMNAKMT2A
SCHEMBL7199674 0.90 MMP1 (0.42) HTTMMP1MMP13ALDH1A1LMNA
SCHEMBL7204539 0.89 MMP1 (0.40) MMP1MMP13MEN1KMT2A
SCHEMBL7206504 0.87 MMP1 (0.47) MMP1MMP13ALDH1A1MMP3MMP2
SCHEMBL7204271 0.87 MMP1 (0.45) MMP1MMP13ALDH1A1MMP3GAA
SCHEMBL7204562 0.86 MMP13 (0.51) HTTMMP1MMP13ALDH1A1LMNA
SCHEMBL7199692 0.86 PARP10 (0.41) MMP1MMP13MMP3MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 TSHR 4677/4885HTT 462/4885MMP1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.